Trial Profile
An Open-Label, Multicenter, Randomized Study of Combination Therapy With Oral Telbivudine Plus Adefovir Dipivoxil Versus Adefovir Dipivoxil Alone in HBeAg-Positive Patients With Chronic Hepatitis B Who Are Lamivudine Resistant.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 04 Jul 2011
Price :
$35
*
At a glance
- Drugs Adefovir dipivoxil (Primary) ; Telbivudine (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Idenix Pharmaceuticals; Novartis
- 21 Jul 2009 Additional trial locations identified as reported by ClinicalTrials.gov.
- 24 Mar 2009 Actual initiation date changed from Sep 2006 to Jan 2007 as reported by ClinicalTrials.gov.
- 25 Nov 2008 Status changed from recruiting to discontinued.